Virtual Library

Start Your Search

Xiaomeng Wang



Author of

  • +

    P2.13 - Targeted Therapy (Not CME Accredited Session) (ID 962)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.13-29 - IL-22 Confers Resistance To EGFR-TKIs In Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification (ID 11857)

      16:45 - 18:00  |  Author(s): Xiaomeng Wang

      • Abstract
      • Slides

      Background

      The effect of epidermal growth factor receptor(EGFR)-targeted strategy is hindered by drug resistance. IL-22 can promote tumor growth and induce resistance to chemotherapy in human lung cancer cells. The aim of our study was to investigate the mechanism of IL-22-induced resistance to EGFR-tyrosine kinase inhibitors(EGFR-TKIs)in the NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The tissues and plasma of patients taking EGFR-TKIs were used to examine the correlation between the drug’s efficacy and IL-22 level. We identified IL-22-induced EGFR-TKIs resistance and the effect of IL-22 on EGFR/AKT/ERK pathways in NSCLC PC-9 and HCC827 cells by CCK-8 assay, flow cytometric analysis, and western blotting. Then, we established the PC-9 xenograft model with IL-22 exposure and used gefitinib combined with vehicle or IL-22 to treat mice.

      4c3880bb027f159e801041b1021e88e8 Result

      We confirmed that IL-22 can inhibit the effect of gefitinib on NSCLC cells and determined the effects of IL-22 on EGFR/AKT/ERK pathways. Then, we showed that IL-22 exposures could promote tumor growth and induce resistance to gefitinib in the PC-9 xenograft model.xenograft model.tif

      8eea62084ca7e541d918e823422bd82e Conclusion

      These results suggest that IL-22 contributes to tumor progression and EGFR-TKIs resistance in NSCLC. Therefore, IL-22 is a potential therapeutic target for EGFR-TKIs resistance.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.13 - Targeted Therapy (Not CME Accredited Session) (ID 979)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.13-23 - EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion. (ID 12491)

      12:00 - 13:30  |  Author(s): Xiaomeng Wang

      • Abstract
      • Slides

      Background

      Pericardial perfusion of hydroxycamptothecin (PCPH) is the effective treatment for malignant pericardial effusion(MPCE). Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) have shown greater efficacy in clinical trials than chemotherapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC), but little information is available on EGFR-mutant NSCLC patients who harboring MPCE. We therefore investigate the advantage of EGFR-TKIs with PCPH for these patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We enrolled patients with MPCE, stage Ⅳ, EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC. These patients were divided into 2 groups by different treatments: EGFR-TKIs in combination with PCPH and chemotherapy combined with PCPH. Retrospectively analyzed the survival of different treatment programs and their prognostic factors.

      4c3880bb027f159e801041b1021e88e8 Result

      Between January 1, 2010, and December 31, 2016, 644 patients were screened. MPCE occurred more frequently in patients with EGFR-mutant than those with EGFR wild-type (10.62% vs. 5.20%; p = 0.046). 29 patients were enrolled, 15 to EGFR-TKIs/HCPT group and 14 to chemotherapy/HCPT group. The progression free survival (PFS) was significantly longer with EGFR-TKIs/HCPT group (360 days) than chemotherapy/HCPT group (90 days; P=0.003). The effusion control rate for pericardial lesions showed statistical difference between two groups (93.33% vs. 71.43%, P = 0.038). Toxicity of EGFR-TKIs/ HCPT groups were characterized by skin rash (40.0% vs. 7.1%; P=0.039), whereas the proportions of patients with leucopenia (42.9% vs. 6.7%; P=0.023) and thrombocytopenia (42.9% vs. 6.7%; P=0.023) were higher in chemotherapy/HCPT group.

      8eea62084ca7e541d918e823422bd82e Conclusion

      EGFR-TKIs combined with PCPH is preferable for advanced NSCLC patients with EGFR-mutant and MPCE.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.